Reconfiguration of AAV Rep-Cap coding sequences significantly increases viral vector yield and enables scalable production in suspension HEK-293 cells
rAAV vectors are demonstrating significant clinical benefit in patients for a range of diseases, however the ability to produce large quantities of functional rAAV particles in a scalable manufacturing system remains challenging. The majority of current rAAV production systems exploit the native Rep-Cap expression configuration found in the viral genome, and adenovirus helper plasmids which contain non-essential regions due to historical cloning strategies. OXGENE has explored the re-design of these two aspects at the DNA level, to increase the yield and quality of rAAV vectors produced. Not only is this system superior to industry standard plasmids in transient transfection in Adherent 293T cells, it is superior in suspension HEK293 cells which allows for scalable production
Download the resource to continue reading.